Patents by Inventor Lauri Marie Schultz

Lauri Marie Schultz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein tyrosine phosphatase inhibitors and methods of use thereof
    Patent number: 7829737
    Abstract: The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: November 9, 2010
    Assignee: Ceptyr, Inc.
    Inventors: Mark Arnold Thomas Blaskovich, Ted Baughman, Thomas Little, Maher Qabar, Lauri Marie Schultz, Feng Hong, William Patt, Gangadhar Nagula, Jennifer Lynn Gage, James Jeffry Howbert
  • PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20090131374
    Abstract: The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.
    Type: Application
    Filed: January 30, 2009
    Publication date: May 21, 2009
    Applicant: CEPTYR, INC.
    Inventors: Mark Arnold Thomas Blaskovich, Ted Baughman, Thomas Little, William Patt, Maher Qabar, Lauri Marie Schultz, Feng Hong, Gangadhar Nagula, Jennifer Lynn Gage, James Jeffry Howbert
  • PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20080161592
    Abstract: The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.
    Type: Application
    Filed: March 6, 2008
    Publication date: July 3, 2008
    Applicant: CEPTYR, INC.
    Inventors: Mark Arnold Thomas Blaskovich, Ted Baughman, Thomas Little, William Patt, Maher Qabar, Lauri Marie Schultz, Feng Hong, Gangadhar Nagula, Jennifer Lynn Gage, James Jeffrey Howbert
  • Method of purifying and identifying a large multiplicity of chemical reaction products simultaneously
    Patent number: 5993662
    Abstract: The invention provides a system utilizing computer databases, high pressure liquid chromatography and mass spectrometry to isolate, purify and identify compounds present in a chemical library of reaction products, especially products of liquid phase (solution) chemical reaction, to produce a purified chemical library with each purified compound tracked to the reaction product from which it originated.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: November 30, 1999
    Assignee: Thetagen, Inc.
    Inventors: Cheryl Denise Garr, Lynn Michele Cameron, David R. Schedin, Lauri Marie Schultz